Latest News

2 October 2014

VivaGel® condom approved for sale with launch imminent

Starpharma today announced the inclusion of the VivaGel® condom in the Australian Register of Therapeutic Goods (ARTG), the final step ahead of market launch in Australia.

Starpharma’s partner in innovating and bringing this product to market, Ansell (ASX:ANN), has made the necessary preparations, including manufacture of launch supplies, and will launch the VivaGel® condom under the LifeStyles® Dual Protect™ name in Australian retail outlets, including Woolworths stores around the country, during October.

Read more

22 September 2014

Starpharma completes A$18 million placement - SPP to follow

Starpharma is pleased to announce it has raised A$18 million via a placement to international and domestic institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will have the opportunity to also participate at the same price, through a Share Purchase Plan (SPP), which will raise up to a further A$5 million.

Read more
Annual Report 2014
Annual Report 2014

13 August 2014

Annual Report and full year financial results

Starpharma today released its annual report and financial results for the year ended 30 June 2014.

Read more

31 July 2014

Appendix 4C - Quarterly Cashflow Statement

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2014.

Read more

In the media

7 August 2014

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

Starpharma CEO Jackie Fairley joins The Business’ Presenter Ticky Fullerton to discuss TGA approval of a VivaGel coated condom in depth, revisiting the shorting issue covered prior on the show, the benefits of the announcement to broader Australian innovation, and a business update on Starpharma’s DEP docetaxel drug development. 

Read more

7 August 2014

Glamour UK: Potential Huge News: This New Condom May Be Able to Kill HIV, Herpes, and Other STDs

Glamour UK, a magazine for women with a UK online readership of 3.38 million, covered the announcement that Starpharma had received TGA approval for VivaGel coated condoms. 

Read more

7 August 2014

The Washington Times: HIV-killing condom to soon hit shelves in Australia

The Washington Times’ picked up the announcement that Starpharma and Ansell have received TGA approval of the VivaGel coated condom from The Daily Mail UK.  

Read more

7 August 2014

The Daily Mail: First condom designed to kill HIV "could be available to buy within months"

In an article that goes into a significant amount of scientific detail for a mainstream news publication, the Daily Mail covered the TGA of VivaGel coated condoms announcement. 

Read more

Shareholder Updates

12 June 2014

Shareholder Update: June 2014

In this issue:

› VivaGel® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel®-coated condom: preparing for launch

› VivaGel® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals

 

Download: Shareholder Update: June 2014 ( pdf file, 2MB)

17 December 2013

Shareholder Update: December 2013

In this issue:

› Dendrimer-Docetaxel to enter human clinical trials

› VivaGel® Phase 3 trial for prevention of recurrent BV

› VivaGel®-coated condom: Consumer feedback

› Impressive results for Dendrimer-Enhanced Oxaliplatin

› Progress continues in agrochemical activities

› Appointment of Rob Thomas

› SPL TV – a new channel

 

Download: Shareholder Update: December 2013 ( pdf file, 1MB)

Sign up to receive news here

© Starpharma Holdings Limited 2014